Clinical Development and Discontinuation of Sales of an HVJ-E Biopharmaceutical Anticancer Agent
An individual project involving an HVJ-E-based biopharmaceutical anticancer agent. After Phase I clinical trials targeting multiple cancer types, development was discontinued and sales ended in March 2022.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.